Vapaliximab

Last updated

Vapaliximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target VAP-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Vapaliximab is a chimeric monoclonal antibody [1] and an experimental immunosuppressive drug. [2] Development was discontinued by 2012. [3]

References

  1. ↑ "Recommended INN: List 49 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 17 (2). 2003. Archived from the original on 2009-10-16. Retrieved 2021-12-12.{{cite journal}}: CS1 maint: bot: original URL status unknown (link)
  2. ↑ Panebianco M, Walker L, Marson AG (October 2023). "Immunomodulatory interventions for focal epilepsy". The Cochrane Database of Systematic Reviews. 10 (10) CD009945. doi:10.1002/14651858.CD009945.pub3. PMC   10577807 . PMID   37842826.
  3. ↑ "Vapaliximab". AdisInsight. Springer Nature Switzerland AG. Retrieved 2 January 2019.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.